113. Muscular dystrophy Clinical trials / Disease details
Clinical trials : 622 / Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01826422 (ClinicalTrials.gov) | March 2013 | 4/4/2013 | Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients | Effect of Eicosapentaenoic Fatty Acid (EPA) and Docosahexaenoic Fatty Acids (DHA) Supplementation on the Inflammation State and Metabolic Disorders in Patients With Duchenne Muscular Dystrophy or Becker Muscular Dystrophy | Muscular Dystrophy, Duchenne | Dietary Supplement: EPA and DHA;Dietary Supplement: Placebo Comparator | Coordinación de Investigación en Salud, Mexico | Instituto Nacional de Rehabilitacion | Completed | 6 Years | 18 Years | Male | 40 | N/A | Mexico |